Apigenin protects against bleomycin‑induced lung fibrosis in rats

Chen,Ling; Zhao,Wei

doi:10.3892/etm.2015.2885

Apigenin protects against bleomycin‑induced lung fibrosis in rats

Authors:
- Ling Chen
- Wei Zhao
View Affiliations

Affiliations: Department of Respiratory Medicine, Pingmei Shenma Medical Group General Hospital, Pingdingshan, Henan 467000, P.R. China, Department of Respiratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: November 20, 2015 https://doi.org/10.3892/etm.2015.2885
Pages: 230-234

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Apigenin is a non‑toxic and non‑mutagenic flavone that exists abundantly in numerous herbs and vegetables. Apigenin exerts anti‑proliferative and anti‑inflammatory properties. The aim of the present study was to investigate the effects of apigenin on bleomycin‑induced lung fibrosis in rats. A single intratracheal instillation of bleomycin (5 mg/kg) was administered and rats were sacrificed on 7 and 28 days post bleomycin instillation. The instillation of bleomycin resulted in decreased body weight and an increase in the lung index. In addition, bleomycin administration increased the hydroxyproline content, myeloperoxidase (MPO) activity, tumor necrosis factor (TNF)‑α and transforming growth factor (TGF)‑β levels and decreased the superoxide dismutase (SOD) activity in the rat lung tissues. Excessive collagen deposits were detected in the lung tissues in bleomycin‑treated rats compared with normal control rats. Notably, the oral administration of apigenin (10, 15 and 20 mg/kg/day) appeared to prevent the fibrotic process. The treatment suppressed the increases in hydroxyproline content, MPO activity, TNF‑α and TGF‑β levels and attenuated the reduction of SOD activity that were induced by bleomycin. Furthermore, excessive collagen deposition was inhibited by the apigenin treatment. Collectively, these results suggest that apigenin may function as a potent anti‑inflammatory and anti‑fibrotic agent against bleomycin‑induced lung fibrosis.

View Figures

View References

1	Gross TJ and Hunninghake GW: Idiopathic pulmonary fibrosis. N Engl J Med. 345:517–525. 2001. View Article : Google Scholar : PubMed/NCBI
2	Dempsey OJ and Miller D: Idiopathic pulmonary fibrosis. BMJ. 347:f65792013. View Article : Google Scholar : PubMed/NCBI
3	Mahendran S and Sethi T: Treatments in idiopathic pulmonary fibrosis: Time for a more targeted approach? QJM. 105:929–934. 2012. View Article : Google Scholar : PubMed/NCBI
4	Villar A, Gasco MA and Alcaraz MJ: Anti-inflammatory and anti-ulcer properties of hypolaetin-8-glucoside, a novel plant flavonoid. J Pharm Pharmacol. 36:820–823. 1984. View Article : Google Scholar : PubMed/NCBI
5	Gerdin B and Svensjö E: Inhibitory effect of the flavonoid O-(beta-hydroxyethyl)-rutoside on increased microvascular permeability induced by various agents in rat skin. Int J Microcirc Clin Exp. 2:39–46. 1983.PubMed/NCBI
6	Agarwal OP: The anti-inflammatory action of nepitrin, a flavonoid. Agents Actions. 12:298–302. 1982. View Article : Google Scholar : PubMed/NCBI
7	Clere N, Faure S, Martinez MC and Andriantsitohaina R: Anticancer properties of flavonoids: Roles in various stages of carcinogenesis. Cardiovasc Hematol Agents Med Chem. 9:62–77. 2011. View Article : Google Scholar : PubMed/NCBI
8	Czyz J, Madeja Z, Irmer U, Korohoda W and Hülser DF: Flavonoid apigenin inhibits motility and invasiveness of carcinoma cells in vitro. Int J Cancer. 114:12–18. 2005. View Article : Google Scholar : PubMed/NCBI
9	Shukla S and Gupta S: Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells. Cell Cycle. 6:1102–1114. 2007. View Article : Google Scholar : PubMed/NCBI
10	Nicholas C, Batra S, Vargo MA, Voss OH, Gavrilin MA, Wewers MD, Guttridge DC, Grotewold E and Doseff AI: Apigenin blocks lipopolysaccharide-induced lethality in vivo and proinflammatory cytokines expression by inactivating NF-kappaB through the suppression of p65 phosphorylation. J Immunol. 179:7121–7127. 2007. View Article : Google Scholar : PubMed/NCBI
11	Duarte S, Arango D, Parihar A, Hamel P, Yasmeen R and Doseff AI: Apigenin protects endothelial cells from lipopolysaccharide (LPS)-induced inflammation by decreasing caspase-3 activation and modulating mitochondrial function. Int J Mol Sci. 14:17664–17679. 2013. View Article : Google Scholar : PubMed/NCBI
12	Zhang X, Wang G, Gurley EC and Zhou H: Flavonoid apigenin inhibits lipopolysaccharide-induced inflammatory response through multiple mechanisms in macrophages. PloS One. 9:e1070722014. View Article : Google Scholar : PubMed/NCBI
13	Liao Y, Shen W, Kong G, Lv H, Tao W and Bo P: Apigenin induces the apoptosis and regulates MAPK signaling pathways in mouse macrophage ANA-1 cells. PloS One. 9:e920072014. View Article : Google Scholar : PubMed/NCBI
14	Kowalski J, Samojedny A, Paul M, Pietsz G and Wilczok T: Effect of apigenin, kaempferol and resveratrol on the expression of interleukin-1beta and tumor necrosis factor-alpha genes in J774.2 macrophages. Pharmacol Rep. 57:390–394. 2005.PubMed/NCBI
15	Wang J, Liao Y, Fan J, Ye T, Sun X and Dong S: Apigenin inhibits the expression of IL-6, IL-8 and ICAM-1 in DEHP-stimulated human umbilical vein endothelial cells and in vivo. Inflammation. 35:1466–1476. 2012. View Article : Google Scholar : PubMed/NCBI
16	Lampronti I, Borgatti M, Vertuani S, Manfredini S and Gambari R: Modulation of the expression of the proinflammatory IL-8 gene in cystic fibrosis cells by extracts deriving from olive mill waste water. Evid Based Complement Alternat Med. 2013:9606032013. View Article : Google Scholar : PubMed/NCBI
17	Huang CS, Lii CK, Lin AH, Yeh YW, Yao HT, Li CC, Wang TS and Chen HW: Protection by chrysin, apigenin and luteolin against oxidative stress is mediated by the Nrf2-dependent up-regulation of heme oxygenase 1 and glutamate cysteine ligase in rat primary hepatocytes. Arch Toxicol. 87:167–178. 2013. View Article : Google Scholar : PubMed/NCBI
18	Han JY, Ahn SY, Kim CS, Yoo SK, Kim SK, Kim HC, Hong JT and Oh KW: Protection of apigenin against kainate-induced excitotoxicity by anti-oxidative effects. Biol Pharm Bull. 35:1440–1446. 2012. View Article : Google Scholar : PubMed/NCBI
19	Jin BH, Qian LB, Chen S, Li J, Wang HP, Bruce IC, Lin J and Xia Q: Apigenin protects endothelium-dependent relaxation of rat aorta against oxidative stress. Eur J Pharmacol. 616:200–205. 2009. View Article : Google Scholar : PubMed/NCBI
20	Ricupero DA, Poliks CF, Rishikof DC, Kuang PP and Goldstein RH: Apigenin decreases expression of the myofibroblast phenotype. FEBS Lett. 506:15–21. 2001. View Article : Google Scholar : PubMed/NCBI
21	Wojcik KA, Skoda M, Koczurkiewicz P, Sanak M, Czyż J and Michalik M: Apigenin inhibits TGF-β1 induced fibroblast-to-myofibroblast transition in human lung fibroblast populations. Pharmacol Rep. 65:164–172. 2013. View Article : Google Scholar : PubMed/NCBI
22	Tarnell EB, Oliver BL, Johnson GM, Watts FL and Thrall RS: Superoxide anion production by rat neutrophils at various stages of bleomycin-induced lung injury. Lung. 170:41–50. 1992. View Article : Google Scholar : PubMed/NCBI
23	Oury TD, Thakker K, Menache M, Chang LY, Crapo JD and Day BJ: Attenuation of bleomycin-induced pulmonary fibrosis by a catalytic antioxidant metalloporphyrin. Am J Respir Cell Mol Biol. 25:164–169. 2001. View Article : Google Scholar : PubMed/NCBI
24	Kinnula VL, Fattman CL, Tan RJ and Oury TD: Oxidative stress in pulmonary fibrosis: A possible role for redox modulatory therapy. Am J Respir Crit Care Med. 172:417–422. 2005. View Article : Google Scholar : PubMed/NCBI
25	Kuwano K, Nakashima N, Inoshima I, Hagimoto N, Fujita M, Yoshimi M, Maeyama T, Hamada N, Watanabe K and Hara N: Oxidative stress in lung epithelial cells from patients with idiopathic interstitial pneumonias. Eur Respir J. 21:232–240. 2003. View Article : Google Scholar : PubMed/NCBI
26	Bellocq A, Azoulay E, Marullo S, Flahault A, Fouqueray B, Philippe C, Cadranel J and Baud L: Reactive oxygen and nitrogen intermediates increase transforming growth factor-beta1 release from human epithelial alveolar cells through two different mechanisms. Am J Respir Cell Mol Biol. 21:128–136. 1999. View Article : Google Scholar : PubMed/NCBI
27	Salvemini D, Riley DP and Cuzzocrea S: SOD mimetics are coming of age. Nat Rev Drug Discov. 1:367–374. 2002. View Article : Google Scholar : PubMed/NCBI
28	Piguet PF, Ribaux C, Karpuz V, Grau GE and Kapanci Y: Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol. 143:651–655. 1993.PubMed/NCBI
29	Yara S, Kawakami K, Kudeken N, Tohyama M, Teruya K, Chinen T, Awaya A and Saito A: FTS reduces bleomycin-induced cytokine and chemokine production and inhibits pulmonary fibrosis in mice. Clin Exp Immunol. 124:77–85. 2001. View Article : Google Scholar : PubMed/NCBI
30	Bhatia M, Zemans RL and Jeyaseelan S: Role of chemokines in the pathogenesis of acute lung injury. Am J Respir Cell Mol Biol. 46:566–572. 2012. View Article : Google Scholar : PubMed/NCBI
31	Martin TR and Matute-Bello G: Experimental models and emerging hypotheses for acute lung injury. Crit Care Clin. 27:735–752. 2011. View Article : Google Scholar : PubMed/NCBI
32	Anscher MS: Targeting the TGF-beta1 pathway to prevent normal tissue injury after cancer therapy. Oncologist. 15:350–359. 2010. View Article : Google Scholar : PubMed/NCBI
33	Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW and Wynn TA: Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med. 207:535–552. 2010. View Article : Google Scholar : PubMed/NCBI